https://www.selleckchem.com/pr....oducts/cremophor-el.
Other adverse factors included pT4 and/or pN2 disease (HR, 2.21; P less then .001), the 3 months of adjuvant treatment (HR, 1.29; P = .0029), tumor obstruction (HR, 1.28; P = .0233), and male sex (HR, 1.24; P = .0151). Patients restaged as having pN2 disease (n = 35, 2.3%) had similar DFS as patients initially classified as pN2. CONCLUSION The presence of TDs is an independent prognostic factor for DFS in patients with stage III CC. The addition of TD to LNM may help to better define the duration of adjuvant therapy.PURPOSE Patient
Like
Comment
Share
